Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease

Biology of Blood and Marrow Transplantation

Volumn 2, Issue 2, 1996, Pages 86-92

  Chao, Nelson J ^a   Parker, Pablo M ^c   Niland, Joyce C ^c   Wong, Ruby M ^b   Dagis, Andrew ^c   Long, Gwynn D ^a   Nademanee, Anayporn P ^c   Negrin, Robert S ^a   Snyder, David S ^c   Hu, Wendy W ^a   Gould, Kelly A ^a   Tierney, D Kathryn ^a   Zwingenberger, Kai ^d   Forman, Stephen J ^c   Blume, Karl G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d GRÜNENTHAL GMBH   (Germany)

Author keywords

Chronic graft vs. host disease; Phase III trial; Thalidomide

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; THALIDOMIDE;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; DOUBLE-BLIND METHOD; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THALIDOMIDE; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030133625     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Sullivan KM: Graft-vs.-host disease. In: SJ Forman, KG Blume, ED Thomas (eds) Bone Marrow Transplantation. Boston: Blackwell Scientific, 339, 1994.
2. Vogelsang GB, Wagner JE: Graft-versus-host disease. Hematol Oncol Clin North Am 4:625, 1990.
3. Vogelsang GB: Acute and chronic graft-versus-host disease. Curr Opin Oncol 5:276, 1993.
4. Siadak M, Sullivan KM: The management of chronic graft-versus-host disease. Blood Reviews 8:154, 1994.
5. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dabiberg S, Deeg HJ, Sanders JE, Doney KC, Appelbaum FR, McGuffin R, McDonald GV, Meyer J, Schubert MM, Gauvrequ J, Shulman HM, Sale GE, Anasetti C, Loughran TP, Strom S, Nims J, Thomas ED: Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombo-cytopenia after allogeneic marrow transplantation. Blood 72:546, 1988.
6. Sullivan KM, Witherspoon RP, Starb R, Deeg HJ, Dablberg S, Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C, Longbran TP, Hill R, Shields A, Yee G, Shulamn H, Nims J, Strom S, Thomas ED: Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72:555, 1988.
7. Field EO, Gibbs JE, Tucker DF, Hellmann K: Effect of thalidomide on the graft versus host reaction. Nature 211:1308, 1966.
8. McCarthy DM, Kanfer EJ, Barrett AJ: Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation. Biomed Pharmacother 43:693, 1989.
9. Heney D, Lewis IJ, Bailey CC: Thalidomide for chronic graft-versus-host disease in children. Lancet 2:1317, 1988. [letter]
10. McCarthy DM, Kanfer E, Taylor J, Barren AJ: Thalidomide for graft-versus-host disease. Lancet 2:1135, 1988. [letter]
11. Lim SH, McWhannell A, Vont AJ, Bonghton BJ: Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation. Lancet 1:117, 1988. [letter]
12. Vogelsang GB, Hess AD, Friedman KJ, Santas GIV: Therapy of chronic graft-v-host disease in a rat model. Blood 74:507, 1989.
13. Vogelsang GB, Hess AD, Gordon G, Santos GIV: Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation 41:644, 1986.
14. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR, Santos GW: Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326:1055, 1992.
15. Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt GM, Snyder DS, Stein AS, Smith EP, Molina A, Stepan DE, Kashyap A, Planas I, Spielberger R, Somlo G, Margolin K, Zwingenberger K, Wilsman K, Negrin RS, Long GD, Niland JC, Blume KG, Forman SJ: Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 86:3604, 1995.
16. Shank B, Chu FC, Dinsmore R, Kapoor N, Kirkpatrick D, Teitelbaum H, Reid A, Bonfiglio P, Simpson L, O'Reilly RJ: Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Physics 9:1607, 1983.
17. Blume KG, Forman SJ, O'Donnell MR, Doroshow JH, Krance RA, Nademanee AP, Snyder DS, Schmidt GM, Fahey JL, Metter GE, Hill LR, Findley DO, Sniecinski IJ: Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 69:1015, 1987.
18. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382, 1987.
19. Forman SJ, Blume KG, Krance RA, Miner PJ, Metter GE, Hill LR, O'Donnell MR, Nademanee AP, Snyder DS: A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone. Transplant Proc 19:2605, 1987.
20. Chao NJ, Schmidt GM, Nilaud JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Fonnan SJ: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225, 1993.
21. Anasetti C, Lin A, Nademanee A, Gluckman E, Mesmer H, Beatty P, Chauncey T, Jacobsen, Chao N, Powles R, Territo M, Wlaker I, Davis J, Light S: A phase II/1II randomized, double-blind, placebo-controlled multicenter trial of humanized anti-Tac for prevention of acute graft-versus-host disease (GVHD) in recipients of marrow transplants from unrelated donors. Blood 86:621a, 1995. [abstract]
22. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549, 1979.
23. Landis RJ, Heyman ER, Koch GG: Average partial association in three-way contingency tables: a review and discussion of alternative tests. Int Stat Rev 46:237, 1978.
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1959.
25. Fernandez LP, Schlegel PG, Baker J, Chen Y, Chao NJ: Does thalidomide affect IL-2 response and production? Exp Hematol 23:978, 1995.
26. Peterson PK, Hu S, Sheng WS, Kravitz FH, Molitor TW, Chatterjee D, Chao CC: Thalidomide inhibits rumor necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J Infect Dis 172:1137, 1995.
27. Palathumpat V, Dejbakbsb-Jones S, Holm B, Strober S: Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease. J Immunol 149:808, 1992.
28. Storb R, Pepe M, Anasetti C, Affelbaum FR, Beatty P, Doney K, Martin P, Stewart P, Sullivan KM, Witherspoon R, Bensinger W, Buckner CD, Clift R, Hansen J, Longton G, Longhran T, Petersen FB, Singer J, Sanders J, Thomas ED: What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 76:1037, 1990.